Skip to main content
OpenTrials
Completed

NCT Number: NCT02073071

Effects of Infant Formula on the Growth and Tolerance in Preterm/Low Birth Weight Infants

This is a two stage open-label, single-arm, multicenter and observational study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 21 day

Sex eligibility

All sexes

Study type

Observational

Primary location

Guangdong General Hospital, Guangzhou, Guangdong, China

Loading trial locations.

About this study

Stage 1: In hospital, preterm/low birth weight infants less than or equal to 34 weeks gestational age at birth, birth weight of ≥ 1000g to <1800g and conditions meeting the enrollment criteria will be fed formula with or without parenteral nutrition until discharge. Stage 2: Post-discharge, all infants with birth weight < or =1500g will be followed on formula per standard of care and accepted standard of care including feeding until the infant's weight >or= 25th percentile of growth expectation based on corrected age (P25) or until infant reaches 9 months corrected age.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for Stage 1:

  • Less than or equal to 34 weeks gestational age at birth, and birth weight ≥ 1000g to < 1800g;
  • Apgar score in 5 minutes after birth ≥ 7;
  • Infant is 21 days or less of age at enrollment;
  • Only singleton or twin births;
  • Infants who can receive early enteral feeding stably (reaching 50% or higher of the required daily total calories) and whose parents/guardians and investigators have selected Similac Special Care (SSC) for feeding;
  • Infant has been classified as appropriate for gestational age (AGA) or if classified as asymmetric small for gestational age (SGA) (Asymmetric SGA: Weight below the 10th percentile, but head circumference is greater than or equal to the 10th percentile) enrollment has been preapproved by sponsor;

Inclusion criteria

for Stage 2:

  • Infants with birth weight < or = 1500g, subjects whose parents/guardians and investigators have selected NeoSure for continued feeding after hospital discharge.

Exclusion criteria

for Stage 1:

  • Serious congenital chromosomal or metabolic abnormalities that may affect growth and development;
  • Congenital gastrointestinal malformations , including but not limited to congenital megacolon or gastric-intestinal perforation;
  • Serious complications associated with preterm birth, including but not limited to necrotizing enterocolitis (NEC), septicemia or sepsis;
  • Other serious disorders of cardiac/respiratory/endocrine/hematological/ gastrointestinal/other systems, or serious diseases requiring surgical intervention;
  • Maternal incapacity: including maternal drug, cocaine or alcohol abuse during pregnancy or current;
  • Infants who received any experimental treatment, participated in other clinical trials or received other study interventions unrelated to this study within 30 days prior to enrollment;
  • Infants who have received or planned to receive breastfeeding or other infant formula (powder) other than SSC with calories intake ≥25% of the required daily total calories
  • Intubation for ventilation at the time of enrollment.

Exclusion criteria

for Stage 2:

  • Infants who have received breastfeeding or other infant formula (powder) during hospitalization other than SSC with calories intake ≥25% of the required daily total calories
  • Infants who have planned to receive breastfeeding or other infant formula (powder) other than NeoSure after discharge with calories intake ≥25% of the required daily total calories

Treatment and study plan

Preterm infant formula per standard of care

Other

Commercially available preterm infant formula

Primary outcomes

  1. Weight

    Time frame: Change from first feeding to discharge (up to ~8 weeks)

Secondary outcomes

  1. Length

    Time frame: Change from first feeding to discharge (up to ~8 weeks)

  2. Head Circumference

    Time frame: Change from first feeding to discharge (up to ~8 weeks)

  3. Hospitalization Length of Stay

    Time frame: Time from Birth to discharge (up to ~8 weeks)

  4. Gastrointestinal Tolerance

    Time frame: From first feeding to discharge (up to ~8 weeks)

    vomiting, abdominal distension, gastric residuals, stool abnormalities, necrotizing enterocolitis

  5. Catch Up Growth

    Time frame: From discharge to 9 months corrected age

    From discharge to the time point that infant's weight >or= 25th percentile of growth expectation based on corrected age (P25) or until infant reaches 9 months corrected age.

Sponsors and collaborators

Lead sponsor

Abbott Nutrition

Industry

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Feb 27, 2014
Registry last updated
Nov 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.